Article Type
Changed
Thu, 07/06/2023 - 17:04

Key clinical point: The clinical characteristics of menstrual migraine (MM) quantitatively differ from those of non-MM, with its symptoms being more severe and inadequately captured by the current diagnostic criteria, necessitating formulation of new criteria for MM diagnosis.

Major finding: The prevalence rates of MM and non-MM were 16.6% and 45.9%, respectively. The MM vs non-MM group was more likely to have more frequent (odds ratio [OR] 7.21), longer duration (OR 2.32), and more severe (OR 1.17) migraine attacks; less frequent nonmigraine headaches (OR 0.31); better treatment outcomes with triptans (OR 1.66); better improvement in migraine attacks during late pregnancy (OR 5.10); and a faster reappearance of migraine attacks postpartum (OR 3.19; all P < .001).

Study details: This case-control study included 12,618 patients with migraine (3434 men and 9184 women).

Disclosures: This study was funded by the Candys Foundation and others. S Brunak and OB Pedersen declared receiving grants, research funds, personal fees, or compensation as a managing board member from or holding stocks in various organizations. The other authors disclosed no conflicts of interest.

Source: Chalmer MA et al. Population-based characterization of menstrual migraine and proposed diagnostic criteria. JAMA Netw Open. 2023;6:e2313235 (May 15). doi: 10.1001/jamanetworkopen.2023.13235

Publications
Topics
Sections

Key clinical point: The clinical characteristics of menstrual migraine (MM) quantitatively differ from those of non-MM, with its symptoms being more severe and inadequately captured by the current diagnostic criteria, necessitating formulation of new criteria for MM diagnosis.

Major finding: The prevalence rates of MM and non-MM were 16.6% and 45.9%, respectively. The MM vs non-MM group was more likely to have more frequent (odds ratio [OR] 7.21), longer duration (OR 2.32), and more severe (OR 1.17) migraine attacks; less frequent nonmigraine headaches (OR 0.31); better treatment outcomes with triptans (OR 1.66); better improvement in migraine attacks during late pregnancy (OR 5.10); and a faster reappearance of migraine attacks postpartum (OR 3.19; all P < .001).

Study details: This case-control study included 12,618 patients with migraine (3434 men and 9184 women).

Disclosures: This study was funded by the Candys Foundation and others. S Brunak and OB Pedersen declared receiving grants, research funds, personal fees, or compensation as a managing board member from or holding stocks in various organizations. The other authors disclosed no conflicts of interest.

Source: Chalmer MA et al. Population-based characterization of menstrual migraine and proposed diagnostic criteria. JAMA Netw Open. 2023;6:e2313235 (May 15). doi: 10.1001/jamanetworkopen.2023.13235

Key clinical point: The clinical characteristics of menstrual migraine (MM) quantitatively differ from those of non-MM, with its symptoms being more severe and inadequately captured by the current diagnostic criteria, necessitating formulation of new criteria for MM diagnosis.

Major finding: The prevalence rates of MM and non-MM were 16.6% and 45.9%, respectively. The MM vs non-MM group was more likely to have more frequent (odds ratio [OR] 7.21), longer duration (OR 2.32), and more severe (OR 1.17) migraine attacks; less frequent nonmigraine headaches (OR 0.31); better treatment outcomes with triptans (OR 1.66); better improvement in migraine attacks during late pregnancy (OR 5.10); and a faster reappearance of migraine attacks postpartum (OR 3.19; all P < .001).

Study details: This case-control study included 12,618 patients with migraine (3434 men and 9184 women).

Disclosures: This study was funded by the Candys Foundation and others. S Brunak and OB Pedersen declared receiving grants, research funds, personal fees, or compensation as a managing board member from or holding stocks in various organizations. The other authors disclosed no conflicts of interest.

Source: Chalmer MA et al. Population-based characterization of menstrual migraine and proposed diagnostic criteria. JAMA Netw Open. 2023;6:e2313235 (May 15). doi: 10.1001/jamanetworkopen.2023.13235

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Migraine, July 2023
Gate On Date
Tue, 01/11/2022 - 20:45
Un-Gate On Date
Tue, 01/11/2022 - 20:45
Use ProPublica
CFC Schedule Remove Status
Tue, 01/11/2022 - 20:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
364621.3
Activity ID
92996
Product Name
Clinical Briefings ICYMI
Product ID
112
Supporter Name /ID
Nurtec ODT (rimegepant) [ 5341 ]